The NSCP has ensured that in an event where the physical office is not available, operations are able to continue offsite. On March 15, the provincial government directed organizations and businesses in Nova Scotia to practice social distancing and support staff in working from home if possible. The NSCP took this direction very seriously and is committed to doing its part to keep Nova Scotians safe.

 During the COVID-19 pandemic, NSCP staff are working remotely to their full capacity, including:

• responding to general phone and email inquiries and requests;
• registering and licensing pharmacists, pharmacy technicians, interns, students, and pharmacies;
• responding to pharmacy practice questions;
• investigating and addressing complaints and concerns; and
• sharing updates through the website and via mass communications to registrants.

Government of Nova Scotia

Nova Scotia COVID-19 Vaccine Program: Information for Health Care Professionals (Evergreen Document) – Updated September 2, 2022

COVID-19 mRNA Vaccines: Summary of Use for Health Care Providers

Information about COVID-19 Vaccine Booster Doses (patient)

Guidance on Third Doses of COVID-19 Vaccine for Moderately to Severely Immunocompromised Nova Scotians

Primary Immunodeficiency: Eligibility for a Third Dose of COVID-19 Vaccine in Nova Scotia

Immunosupressive Medication List – Updated October 19, 2021

COVID-19 Vaccine Rollout Information

Direction on how to manage a vaccine error should it occur

Documentation Errors in CANImmunize Clinic Flow

Correction of Documentation Errors within CANImmunize Clinic Flow

NSCP Advisory

Registrar’s Advisory: Community Pharmacy Involvement in COVID-19 Vaccination

NSH COVID-19 Vaccine Pharmacist Consult Service

Nova Scotia Health’s (NSH) Pharmacy Department is launching the COVID-19 Vaccine Pharmacist Consult Service. This consult service will be available from 8:30 am until 4:30 pm, 7 days a week. You can reach this consult service by calling 1-833-768-1151. Please note: if calling outside of the scheduled hours, you will be directed to call the following day.

When calling, pharmacists will be directed to a NSH pharmacist who will:

• Answer vaccination consent category 1-3 questions and answer consent category 4-5 questions in collaboration with Vaccination Clinical Support Physicians (VACS)
• Answer storage, stability, and administration questions
• Provide general vaccine information

More information on the consult service can be found here.

Webinars

Building COVID-19 Vaccine Confidence Before, During and After Pregnancy (March 17, 2022)

Preparing for Pediatric COVID-19 Immunization and Adult Booster Doses (November 17, 2021)

Revaccination with COVID-19 Vaccines After Anaphylaxis (November 15, 2021)

Seasonal Influenza Immunization 2021-2022 (October 27, 2021)

COVID-19 Variants and Vaccines (June 23, 2021)

NACI Recommendations on COVID-19 Vaccine Interchangeability (June 21, 2021)

Addressing COVID-19 Vaccine Hesitancy in Clinical Practice (May 19, 2021)

Recommendation of the National Advisory Committee on Immunization (NACI) on Extended Dose Intervals for COVID-19 Vaccines (May 5, 2021)

COVID-19 Vaccine Emerging Issues Webinar: Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) (April 21, 2021)

COVID-19 Vaccines – Delayed Injection Site Reactions (March 11, 2021)

COVID-19 Vaccines – Planning for Immunization Clinics (March 1, 2021)

COVID-19 Vaccines Foundational Webinar (February 23, 2021)

COVID-19 Vaccines – Allergies, Anaphylaxis and LDV Syringe Discussion (February 10, 2021)

Recommendations of the National Advisory Committee on Immunization (NACI) on the use of the Moderna COVID-19 Vaccine (December 30, 2020)

Recommendations of the National Advisory Committee on Immunization (NACI) on the use of the Pfizer-BioNTech COVID-19 Vaccine (December 18, 2020)

COVID-19 Vaccine Foundations for Health Care Providers (December 14, 2020)

Health Canada

Quick Reference Guide on the Use of COVID-19 Vaccines for Youth and Adults (12 years and over)

Quick Reference Guide on the Use of COVID-19 Vaccines for Children 5 to 11 Years of Age 

COVID-19 Vaccine Tool Kit for Health Care Providers – Updated May 7, 2021

Information for Health Care Providers on Allergies and Anaphylaxis Following Administration of COVID-19 Vaccines

COVID-19 Vaccines and Low Dead Volume (LDV) Syringes

Interim National Vaccine Storage, Handling and Transportation Guidelines for Ultra-Low Temperature and Frozen Temperature COVID-19 Vaccines

Pfizer-BioNTech

Adult Vaccine

Pfizer-BioNTech COVID-19 vaccine: What you should know (patient)

Pfizer Comirnaty Information about COVID-19 Vaccine Booster Doses

Important Information about Myocarditis and Pericarditis

Pfizer COVID-19 Vaccine Monograph Canada

Pfizer COVID -19 Vaccine Information Sheet (patient)

Pfizer Health Care Professionals Website

Pfizer-BioNTech COVID-19 vaccine: Information About Low Dead-Volume Syringes

Pediatric Vaccine

Pfizer COVID-19 Pediatric Vaccine Information Sheet (patient)

Pfizer Health Care Professionals Website – Updated November 19, 2021 for pediatric vaccine

Access to Canadian-specific labelling information during the distribution of Pfizer-BioNTech COVID-19 Vaccine for Children Aged 5 to Less Than 12 Years

Moderna

Moderna COVID-19 vaccine: What you should know (patient)

Moderna Spikevax Vaccines Information about COVID-19 Vaccine Booster Doses

Important Information about Myocarditis and Pericarditis

Moderna COVID-19 Vaccine Monograph Canada

Moderna Resources for Canadian Healthcare Professionals and Patients

Moderna COVID-19 Vaccine Information Sheet (patient)

Moderna COVID-19 Vaccine Storage and Handling

Importation of COVID-19 Vaccine Moderna with up to 15 Doses per Vial and English-only Vial and Carton Labels (US-Labelled Vaccine Supply)

AstraZeneca

AstraZeneca COVID-19 Vaccine: What you should know (patient)

AstraZeneca COVID-19 Vaccine Monograph Canada

AstraZeneca COVID-19 Information Sheet (patient)

PHAC Infobulletin on VITT for Health Care Providers

Access to Canadian-specific labelling information during the initial distribution of the AstraZeneca COVID-19 Vaccine (US-labelled vaccine supplies) (For April 6th Shipment ONLY)

Janssen

Janssen COVID-19 Vaccine Information Sheet (patient)

Janssen COVID-19 Vaccine: What you should know (patient)

Janssen COVID-19 Vaccine Monograph Canada

Medicago

Medicago COVID-19 Vaccine Monograph Canada

Centre for Effective Practice

COVID-19 Vaccines

USP

USP COVID-19 Vaccine Handling Toolkit

It is important that we recognize the added challenges for those working in the healthcare system during a pandemic like COVID-19. Pharmacy practitioners are ultimately accountable for their actions at all times, including during an outbreak, and they make decisions based on available information, the needs of the patient, their duty to provide care, and their obligation to protect themselves and their families.

The following resources are meant to support the public, pharmacy practitioners and employers in understanding their accountabilities during this time:

Standard of Care During a Crisis

A Pharmacy Professional’s Duty During a Crisis: An Ethical Framework

Amendments to Drug Administration Standards

Temporary Suspension of Drug Administration Notification During COVID-19

Emergency Protocol: Prescribing Narcotics, Controlled and Targeted Drugs

Fax Transmission of Prescriptions Policy – Amendments

MAiD Standards and the Return of Medication Policy – Amendments

Nova Scotia Prescription Monitoring Program (NSPMP) and Drug Information System (DIS) – Changes to Enable Pharmacist Prescribing of CDSA Drugs

Opioid Agonist Maintenance Treatment (OAMT) Services During the COVID-19 Pandemic

Prescribing in a Public Health Emergency/Crisis Standards 

Prescribing Renewals – 180 Day Limit

 

Information from Health Canada

Subsection 56(1) Class Exemption for Patients, Practitioners and Pharmacists Prescribing and Providing Controlled Substances in Canada During the Coronavirus Pandemic

Controlled Substances Bulletin – Requirements for Chain of Signatures in Light of COVID-19

NSCP Professional Notices

 

September 13, 2022 

Public Health Guidance on Continued COVID-19 Masking

August 2, 2022

Administration of COVID and Flu Vaccines for Children Under 2 Years of Age

May 10, 2022

Pharmacist Prescribing Inhaled Budesonide for Mild SARS-CoV-2 Respiratory Symptoms

April 29, 2022

Reduced Age Limit for Drug Administration of Flu and COVID Vaccines

April 6, 2022

Paxlovid™ (nirmatrelvir/ritonavir) Information and Resources

March 2, 2022

NSH COVID-19 Antiviral Therapy Consult Service; Inhaled Budesonide

January 27, 2022

Paxlovid™ (nirmatrelvir/ritonavir) Oral Treatment for COVID-19

December 20, 2021

Documentation Errors within CANImmunize Clinic Flow

December 17, 2021

Omicron Infection Prevention and Control Measures

December 9, 2021

Incorporation of COVID-19 Provisions into Standards

November 30, 2021

Mitigating Risks When Administering Multiple Vaccines

November 18, 2021

Updated NSCN/NSCP Joint Statement on Nurses Employed in Community Pharmacies

November 17, 2021

Updated Health Canada s.56 Exemption: Transfers from Other Provinces

November 4, 2021

Guidance: Asymptomatic COVID-19 Testing in Community Pharmacies

June 22, 2021

Extension of Health Canada CDSA Exemption

May 4, 2021

Preparation of COVID-19 Vaccine Syringes

April 28, 2021

Temporary Pharmacy Closures; COVID-19 Vaccine Screening

April 26, 2021

Critical Use of PPE During Third Wave

April 1, 2021

Update: Pharmacy Involvement in the COVID-19 Vaccine Rollout

March 15, 2021

Registrar’s Advisory on COVID-19 Immunization; Nurses as Immunizers in Pharmacies

March 3, 2021

Confirmation on Requirement for Duplicate Prescription Forms

March 2, 2021

Update: Pharmacy Involvement in the COVID-19 Vaccine Rollout

February 11, 2021

Pharmacy Involvement in the COVID-19 Vaccine Rollout

December 29, 2020

Moderna COVID-19 Vaccine Webinar – Dec 30

December 27, 2020

Upcoming Moderna Webinar – Dec 29

October 9, 2020

NS Drug Information System (NS DIS) Prescription Transfers for Monitored CDSA Drugs

September 9, 2020

Update on Pharmacy Practice Provisions for COVID-19

July 30, 2020

Mandatory Use of Non-Medical Masks in Community Pharmacies

June 16, 2020

Newly Licensed Pharmacists

May 19, 2020

Change to 30 Days Supply Measure

May 1, 2020

Guidance for Staff Who Test Positive for COVID-19 and Close Contacts

April 27, 2020

Clinical Practice Consultant Service

April 20, 2020

Opioid Agonist Therapy (OAT) Community of Practice Resource and Physician Call List

April 18, 2020

Amendments to Drug Administration Standards

April 14, 2020

Temporary Suspension of 180 Days Renewal Limit; Keeping DIS Current

April 9, 2020

Pharmacy Infection Control Measures During COVID-19

April 8, 2020

Messages from Public Health

April 6, 2020

COVID-19 Practice Questions and Pharmacy Closures

April 1, 2020

CCP Discontinuation; Prescribing During the COVID-19 Pandemic; COVID-19 Screening

March 28, 2020

COVID-19 Pharmacy Practice Provisions and Guidance

March 24, 2020

Emergency Protocol for Prescribing CDSA Drugs; Changes to NSPMP and DIS; Fax Transmission Policy

March 22, 2020

Health Canada CDSA Exemption; Verifying Authenticity; Provision of OAMT

March 18, 2020

Dispensed Days Supply; Prescribing in a Public Health Emergency/Crisis

March 17, 2020 (updated March 21, 2020; updated March 31, 2020)

Inappropriate COVID-19 Prescribing

Joint Statement on the Unproven Therapies for COVID-19

March 14, 2020

COVID-19 Guidance from NSCP

 

Special Bulletins from the Office of the Chief Medical Officer of Health

 

April 29, 2022

Memo from the Deputy Chief Medical Officer of Health: Updated Guidance from the National Advisory Committee on Immunization (NACI) on COVID-19 Vaccine Booster Doses

April 5, 2022

Memo from the Deputy Chief Medical Officer of Health: COVID-19 Vaccine Booster Doses for Moderately to Severely Immunocompromised Individuals

February 9, 2022

Memo from the Deputy Chief Medical Officer of Health: Post-Infection Vaccination Timing

February 8, 2022

Memo from the Deputy Chief Medical Officer of Health: COVID-19 Primary Series for Immunocompromised Children Aged 5-11 

February 7, 2022

Memo from the Deputy Chief Medical Officer of Health: COVID-19 Booster Doses for Adolescents 12 to 17 Years of Age

January 24, 2022

Memo from the Deputy Chief Medical Officer of Health: Booster Dose Interval for Individuals Who Are Pregnant

January 10, 2022

Memo from the Deputy Chief Medical Officer of Health: mRNA Vaccines Following Post-Vaccine Myocarditis/Pericarditis

December 8, 2021

Memo from the Chief Medical Officer of Health: COVID-19 Reporting Requirements

November 19, 2021

Memo from the Chief Medical Officer of Health: Booster COVID-19 Vaccine Doses in Nova Scotia – Update

November 5, 2021

Special Bulletin from the Chief Medical Officer of Health: Booster COVID-19 Vaccine Doses in Nova Scotia 

October 15, 2021

Memo from the Chief Medical Officer of Health: Appointment bookings for additional COVID-19 vaccine doses for moderately to severely immunocompromised individuals

October 7, 2021

Special Bulletin from the Chief Medical Officer of Health: 2021-2022 Influenza Season update for Health Care Providers

October 6, 2021

Memo from the Chief Medical Officer of Health: Additional doses of COVID-19 vaccine for immunocompromised Nova Scotians

September 17, 2021

Memo from the Chief Medical Officer of Health: Valid Medical Contraindication for COVID-19 Vaccination

August 31, 2021

Memo from the Chief Medical Officer of Health: Nova Scotia COVID-19 Definitions of Fully Vaccinated, Optimal Protection and Contraindications

August 20, 2021

Special Bulletin from the Chief Medical Officer of Health: Optimizing Protection Against COVID-19 for Individuals Residing in Nova Scotia Who Have Received Non-Health Canada Authorized and/or Janssen COVID-19 Vaccines

March 31, 2021

Special Bulletin from the Chief Medical Officer of Health: Update Regarding Use of AstraZeneca Vaccine, AEFI Reporting

March 22, 2021

Special Bulletin from the Chief Medical Officer of Health: Updates on COVID-19 Vaccine Program Including AstraZeneca

February 26, 2021

Special Bulletin from the Chief Medical Officer of Health: COVID-19 Immunization Program and COVID-19 Testing

December 17, 2020

Special Bulletin from the Chief Medical Officer of Health: COVID-19 Immunization

September 4, 2020

Special Bulletin from the Office of the Chief Medical Officer of Health: 2019 Novel Coronavirus (SARS-CoV-2)

May 22, 2020

Special Bulletin from the Office of the Chief Medical Officer of Health: 2019 Novel Coronavirus (SARS-CoV-2)

April 8, 2020

Special Bulletin from the Office of the Chief Medical Officer of Health: 2019 Novel Coronavirus (SARS-CoV-2)

March 11, 2020

Special Bulletin from the Office of the Chief Medical Officer of Health: 2019 Novel Coronavirus (SARS-CoV-2)

March 9, 2020

Special Bulletin from the Office of the Chief Medical Officer of Health: 2019 Novel Coronavirus (SARS-CoV-2)

February 27, 2020

Special Bulletin from the Office of the Chief Medical Officer of Health: 2019 Novel Coronavirus (SARS-CoV-2)

February 6, 2020

Special Bulletin from the Office of the Chief Medical Officer of Health: 2019 Novel Coronavirus (2019-nCoV) 

January 29, 2020

Special Bulletin from the Office of the Chief Medical Officer of Health: 2019 Novel Coronavirus (2019-nCoV) 

January 27, 2020

Special Bulletin from the Office of the Chief Medical Officer of Health: 2019 Novel Coronavirus (2019-nCoV)

Community Pharmacy Involvement in COVID-19 Vaccination

Registrar’s Advisory: Community Pharmacy Involvement in COVID-19 Vaccination

NSCN/NSCP Joint Statement on Nurses Employed in Community Pharmacies to Support the COVID-19 Pandemic Response

Asymptomatic COVID-19 Point of Care Testing 

Registrar’s Advisory: Asymptomatic COVID-19 Point of Care Testing in Community Pharmacies

Re-opening Guidance

Re-opening Guidance for Health Care Services Settings – Prepared May 27, 2020

Pharmacy Infection Control

NSCP Pharmacy Infection Control Measures During COVID-19

Temporary Pharmacy Closures Policy

Temporary closure of community pharmacies has the potential to adversely impact patient care and safety. As the role of the pharmacist and the services they provide expands, the significance of temporary pharmacy closures also rises. Pharmacies enter into a contract with patients regarding the provision of their care that includes that the pharmacy will provide the patient with reasonable access to their medication and record when needed and/or requested.

In consideration of the public safety issues associated with temporary pharmacy closures, this policy sets out requirements for pharmacy managers and owners who may need to close the pharmacy temporarily due to the planned absence of a pharmacist or to unplanned events that are outside the control of the pharmacy manager and/or owner.

Temporary Pharmacy Closures Policy

Notification of Temporary Pharmacy Closure Form

Virtual Services

Registrar’s Advisory: Pharmacy Practice Guidelines for Virtual Pharmacy During COVID-19

Posters/Signage

Face Mask Required

How to Wear a Non-Medical Mask

Symptoms/Do Not Enter (PANS)

Cleaning Guidelines (NSCP and PANS)

Temporary Closure

Temporary Closure with Prescription Pick Up Contact Information

Temporary Closure with Partner Pharmacy Contact Information

Temporary Closure with OAMT Contact Information

Temporary Closure with Reopening Information

In December 2019, Novel Coronavirus (COVID-19) emerged in the city of Wuhan, China. Since then, there have been reports in several countries, including Canada. On March 11, the World Health Organization declared COVID-19 a pandemic. Symptoms of COVID-19 range from mild to severe and can include fever, cough, difficulty breathing, pneumonia and kidney failure. In many cases, clients recover, and in very severe cases, it may cause death.

Please see the following resources for more information about COVID-19:

World Health Organization

Spectrum

Maritime SPOR SUPPORT Unit (MSSU)

CADTH: Drug Treatments for COVID-19

Government Websites

Government of Nova Scotia

Government of Canada

Government of Canada: Guidance Documents